Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Will Have Risk-Based Import Screening System Up And Running Throughout U.S. By Year's End

This article was originally published in The Pink Sheet Daily

Executive Summary

Limited roll out of the PREDICT system shows it has been effective in identifying the riskier imports that should be the focus of inspectors' attention, Commissioner Hamburg tells House panel

You may also be interested in...

FDA’s PREDICT Import Screening System Working As Predicted

An initial look at data from the first year of the import screening system’s full operation finds PREDICT is effective in directing FDA inspectors to high-risk products, Deputy Associate Commissioner for Regulatory Affairs Steve Solomon says.

PDUFA Stars Aligning As House Draft Gives FDA Direct Authority Over Importers

Latest version of potential House user fee bill eliminates revisions to FDA’s mission statement and includes provisions for approving breakthrough technologies and destroying unsafe drug imports at the border.

FDA Enforcement Powers Remain In Limbo As User Fee Bill Glides Through Markup

Senate committee approves comprehensive user fee bill, but FDA authority to destroy some unsafe drug imports and track-and-trace provisions remain outstanding issues. Meanwhile, the House is going back to the drawing board on several provisions.

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts